WATCH: Trump orders reclassification of marijuana, downgrading its drug schedule

President Trump signed an executive order directing federal agencies to reclassify marijuana from a Schedule I to a Schedule III drug, a move intended to expand medical research and broaden access to CBD while potentially lowering the heavy federal tax burden on the cannabis industry. The change would not legalize recreational use and must still go through a DEA rulemaking process with public comment; the administration faces intra‑party opposition from over 20 Republican senators, leaving timing and final regulatory details uncertain. For investors, the order lifts a major overhang on sector economics and could improve tax, banking and R&D prospects for cannabis and related biotech companies if implemented, but material financial effects depend on the pace and scope of DEA and DOJ action.

Analysis

Market structure: Rescheduling from Schedule I to III materially favors US multi-state operators (MSOs), CBD/hemp processors, payments and cannabis-real-estate platforms. Expect 10–20% near-term EBITDA uplift assumptions for MSOs once 280E tax relief is clarified (translates to 200–800 bps margin expansion depending on current state), while federally compliant REITs (IIPR) see NAV rerating as bank financing becomes feasible. Pricing power will bifurcate: well-capitalized national chains gain share and compress prices for small legacy operators.

Risk assessment: Tail risks include DOJ/DEA litigation, Congressional riders reversing or neutering regulatory relief, or IRS delaying 280E guidance — any of which could wipe 30–50% of anticipated valuation upside for levered MSOs within 6–12 months. Short-term (days–weeks) volatility will spike around DEA/IRS filings; medium-term (3–12 months) depends on final rule and tax code treatment; long-term (1–3 years) rests on bank access, Medicaid/Medicare policy and pharma entrants. Hidden dependencies: banking access, state-to-federal regulatory harmonization, and C-suite execution on consolidation will determine winners.

Trade implications: Favor long IIPR and selected US MSOs (CURLF, CRLBF, TCNNF) and short/underweight large Canadian LPs (CGC, TLRY) that face renewed US competition and FX/cost pressure; target 2–4% position sizes per idea. Use LEAPS (9–12 months) calls on MSOs/REITs to capture tax-rule upside, and buy volatility on any pre-DEA pullback; consider pair trades (long CURLF, short CGC) to isolate US regulatory upside.

Contrarian angles: The market may be underpricing implementation friction — federal rescheduling could increase compliance burdens, benefit big-cap consolidators and reduce pricing power for fragmented local growers. If Republican legal pushback or DEA procedural delays extend >6 months, expect a >20% drawdown in richly valued MSOs; conversely, a swift IRS 280E rollback would trigger a >30% re-rating in select names within 3–9 months.

Key Decisions for Investors

• Establish a 3% long position in Innovative Industrial Properties (IIPR) within 30–90 days; add on confirmation of DEA final rule or IRS 280E guidance. Target 30–45% upside in 12 months; stop-loss at -18%.
• Build a 2–3% long position in Curaleaf (CURLF) or Cresco Labs (CRLBF) via 9–12 month LEAPS calls (buy-dated >=9 months) to capture tax/treatment re-rate; allocate max 1.5% notional to options and 1.5% to stock. Trim into +30% move or on evidence of widening credit access.
• Initiate a relative-value pair: long US MSO (CURLF, 2%) vs short Canadian LP (CGC or TLRY, 1.5%) to exploit expected US regulatory premium; widen if beta-adjusted spread narrows <10% within 6 months. Close if DEA process delayed >180 days.
• Buy protection (buy puts) or reduce exposure in levered MSOs if DEA/IRS guidance not issued within 90 days; consider 60–120 day puts sized 0.5–1% notional to hedge regulatory execution risk.
• Watch three catalysts as trade triggers: (1) DEA final rule publication (expected within 60–180 days), (2) IRS guidance on 280E (threshold event), (3) major bank pilot announcement accepting cannabis clients. Take or add risk within 7 trading days of any catalyst.